ATE391493T1 - Suspension von loteprednol-etabonat und tobramycin für die topische ophthalmische anwendung - Google Patents

Suspension von loteprednol-etabonat und tobramycin für die topische ophthalmische anwendung

Info

Publication number: ATE391493T1
Authority: AT; Austria
Prior art keywords: tobramycin; loteprednol etabonate; suspension; topical ophthalmic; ophthalmic use
Prior art date: 2003-10-31

Application number

AT04810041T

Other languages

English (en)

Inventor

Ramesh Krishnamoorthy

Original Assignee

Bausch & Lomb

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-10-31

Filing date

2004-10-27

Publication date

2008-04-15

2004-10-27 Application filed by Bausch & Lomb filed Critical Bausch & Lomb

2008-04-15 Application granted granted Critical

2008-04-15 Publication of ATE391493T1 publication Critical patent/ATE391493T1/de

Links

229960003744 loteprednol etabonate Drugs 0.000 title abstract 2
229960000707 tobramycin Drugs 0.000 title abstract 2
NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 title abstract 2
230000000699 topical effect Effects 0.000 title abstract 2
DMKSVUSAATWOCU-HROMYWEYSA-N loteprednol etabonate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)OCCl)(OC(=O)OCC)[C@@]1(C)C[C@@H]2O DMKSVUSAATWOCU-HROMYWEYSA-N 0.000 title 1
239000000725 suspension Substances 0.000 title 1
238000009472 formulation Methods 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
206010061218 Inflammation Diseases 0.000 abstract 1
239000003242 anti bacterial agent Substances 0.000 abstract 1
230000003110 anti-inflammatory effect Effects 0.000 abstract 1
229940088710 antibiotic agent Drugs 0.000 abstract 1
208000015181 infectious disease Diseases 0.000 abstract 1
230000004054 inflammatory process Effects 0.000 abstract 1
230000000087 stabilizing effect Effects 0.000 abstract 1
-1 steroid loteprednol etabonate Chemical class 0.000 abstract 1
150000003431 steroids Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Ophthalmology & Optometry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Otolaryngology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

AT04810041T 2003-10-31 2004-10-27 Suspension von loteprednol-etabonat und tobramycin für die topische ophthalmische anwendung ATE391493T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US10/698,322 US20050095205A1 (en)	2003-10-31	2003-10-31	Combination of loteprednol etabonate and tobramycin for topical ophthalmic use

Publications (1)

Publication Number	Publication Date
ATE391493T1 true ATE391493T1 (de)	2008-04-15

Family

ID=34550614

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04810041T ATE391493T1 (de)	2003-10-31	2004-10-27	Suspension von loteprednol-etabonat und tobramycin für die topische ophthalmische anwendung

Country Status (13)

Country	Link
US (2)	US20050095205A1 (de)
EP (1)	EP1677761B1 (de)
JP (2)	JP2007509952A (de)
KR (1)	KR101086990B1 (de)
CN (1)	CN1897917A (de)
AT (1)	ATE391493T1 (de)
AU (1)	AU2004287443B2 (de)
BR (1)	BRPI0416123B8 (de)
CA (1)	CA2544139C (de)
DE (1)	DE602004013035T2 (de)
ES (1)	ES2303967T3 (de)
TW (1)	TWI359022B (de)
WO (1)	WO2005044231A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050095205A1 (en) *	2003-10-31	2005-05-05	Ramesh Krishnamoorthy	Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
US20050197303A1 (en) *	2003-10-31	2005-09-08	Bausch & Lomb Incorporated	Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
WO2007032997A1 (en) *	2005-09-13	2007-03-22	Bausch & Lomb Incorporated	Ophthalmic formulation containing loteprednol etabonate for treatment of dry eye
US20070093461A1 (en) *	2005-10-26	2007-04-26	Bausch & Lomb Incorporated	Effect of Loteprednol etabonate on vascular dysfunction
US7767217B2 (en) *	2006-03-14	2010-08-03	Foresight Biotherapeutics	Ophthalmic compositions comprising povidone-iodine
EP2003970A4 (de) *	2006-03-28	2012-07-11	Javelin Pharmaceuticals Inc	Formulierungen aus niedrigdosierten nicht-steroiden entzündungshemmern und beta-cyclodextrin
AU2007230716B2 (en) *	2006-03-28	2012-05-03	Javelin Pharmaceuticals, Inc.	Formulations of low dose diclofenac and beta-cyclodextrin
WO2008085913A1 (en) *	2007-01-04	2008-07-17	Rib-X Pharmaceuticals, Inc.	Methods for treating, preventing, or reducing the risk of opthalmic, otic, and nasal infections
CN101317847B (zh) *	2007-06-06	2010-10-13	深圳市瑞谷医药技术有限公司	一种眼用或耳鼻用药物组合物及其用途
US20090239836A1 (en) *	2008-03-24	2009-09-24	Mary Lee Ciolkowski	Multifunctional Ophthalmic Compositions
CN102118973A (zh) *	2008-06-12	2011-07-06	前瞻生物治疗公司	一种眼科组合物中新的防腐剂替代物聚维酮碘
WO2012073856A1 (ja) *	2010-11-29	2012-06-07	千寿製薬株式会社	ジフルプレドナートおよびトブラマイシンを含有する水中油型エマルジョン組成物
WO2013065028A1 (en) *	2011-11-04	2013-05-10	Micro Labs Limited	Fixed dose combination containing azithromycin and loteprednol for treatment of ocular infections
HK1208162A1 (en)	2012-05-03	2016-02-26	Kala Pharmaceuticals, Inc.	Pharmaceutical nanoparticles showing improved mucosal transport
US11596599B2 (en)	2012-05-03	2023-03-07	The Johns Hopkins University	Compositions and methods for ophthalmic and/or other applications
US9827191B2 (en)	2012-05-03	2017-11-28	The Johns Hopkins University	Compositions and methods for ophthalmic and/or other applications
WO2013166408A1 (en)	2012-05-03	2013-11-07	Kala Pharmaceuticals, Inc.	Pharmaceutical nanoparticles showing improved mucosal transport
SG11201809811VA (en) *	2016-05-05	2018-12-28	Veloce Biopharma Llc	Compositions and methods for treatment of inflammation or infection of the eye
US10555947B2 (en) *	2017-05-19	2020-02-11	Ocugen, Inc.	Ophthalmic compositions and methods of use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4996335A (en) *	1980-07-10	1991-02-26	Nicholas S. Bodor	Soft steroids having anti-inflammatory activity
US4710495A (en) *	1980-07-10	1987-12-01	Otsuka Pharmaceutical Co., Ltd.	Soft steroids having anti-inflammatory activity
US6610675B1 (en) *	1980-07-10	2003-08-26	Nicholas S. Bodor	Inactive metabolite approach to soft drug design
US5192535A (en) *	1988-02-08	1993-03-09	Insite Vision Incorporated	Ophthalmic suspensions
US5149693A (en) *	1988-03-09	1992-09-22	Alcon Laboratories, Inc.	Combination of tobramycin and fluorometholone for topical ophthalmic use
US5340572A (en) *	1993-02-08	1994-08-23	Insite Vision Incorporated	Alkaline ophthalmic suspensions
US5540930A (en) *	1993-10-25	1996-07-30	Pharmos Corporation	Suspension of loteprednol etabonate for ear, eye, or nose treatment
TW503113B (en) *	1997-01-16	2002-09-21	Senju Pharma Co	Aqueous suspension for nasal administration
JP3147076B2 (ja) *	1997-03-14	2001-03-19	千寿製薬株式会社	ロテプレドノールエタボネート水性懸濁液
KR100508227B1 (ko) *	1997-03-14	2006-03-23	센주 세이야꾸 가부시키가이샤	로테프레드놀에타보네이트수성현탁액
US6239113B1 (en) *	1999-03-31	2001-05-29	Insite Vision, Incorporated	Topical treatment or prevention of ocular infections
US20010049366A1 (en) *	2000-02-09	2001-12-06	Alcon Universal Ltd.	Topical solution formulations containing an antibiotic and a corticosteroid
US20020098154A1 (en) *	2001-01-20	2002-07-25	Dyer Gordon Wayne	Methods and apparatus for medicating the nasal sinuses
MXPA05013898A (es) *	2003-06-19	2006-05-25	Nicholas S Bodor	Mejoramiento de la actividad y/o duracion de la accion de esteroides antiinflamatorios suaves para la aplicacion topica u otra aplicacion local.
US20050095205A1 (en) *	2003-10-31	2005-05-05	Ramesh Krishnamoorthy	Combination of loteprednol etabonate and tobramycin for topical ophthalmic use

2003
- 2003-10-31 US US10/698,322 patent/US20050095205A1/en not_active Abandoned
2004
- 2004-10-27 ES ES04810041T patent/ES2303967T3/es not_active Expired - Lifetime
- 2004-10-27 KR KR1020067010559A patent/KR101086990B1/ko not_active Expired - Fee Related
- 2004-10-27 CN CNA2004800382496A patent/CN1897917A/zh active Pending
- 2004-10-27 DE DE602004013035T patent/DE602004013035T2/de not_active Expired - Lifetime
- 2004-10-27 WO PCT/US2004/035562 patent/WO2005044231A1/en not_active Ceased
- 2004-10-27 AU AU2004287443A patent/AU2004287443B2/en not_active Ceased
- 2004-10-27 BR BRPI0416123A patent/BRPI0416123B8/pt not_active IP Right Cessation
- 2004-10-27 AT AT04810041T patent/ATE391493T1/de active
- 2004-10-27 JP JP2006538199A patent/JP2007509952A/ja not_active Withdrawn
- 2004-10-27 CA CA2544139A patent/CA2544139C/en not_active Expired - Fee Related
- 2004-10-27 EP EP04810041A patent/EP1677761B1/de not_active Expired - Lifetime
- 2004-10-28 TW TW093132835A patent/TWI359022B/zh not_active IP Right Cessation
2009
- 2009-09-01 US US12/584,186 patent/US20100003334A1/en not_active Abandoned
2012
- 2012-02-02 JP JP2012020684A patent/JP5726774B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
EP1677761A1 (de)	2006-07-12
CA2544139C (en)	2012-10-09
CA2544139A1 (en)	2005-05-19
JP2012087151A (ja)	2012-05-10
TW200526235A (en)	2005-08-16
EP1677761B1 (de)	2008-04-09
KR101086990B1 (ko)	2011-11-29
AU2004287443A1 (en)	2005-05-19
US20100003334A1 (en)	2010-01-07
BRPI0416123A (pt)	2007-01-02
DE602004013035D1 (de)	2008-05-21
WO2005044231A1 (en)	2005-05-19
BRPI0416123B8 (pt)	2021-05-25
US20050095205A1 (en)	2005-05-05
BRPI0416123B1 (pt)	2018-11-21
KR20060110312A (ko)	2006-10-24
ES2303967T3 (es)	2008-09-01
JP5726774B2 (ja)	2015-06-03
CN1897917A (zh)	2007-01-17
DE602004013035T2 (de)	2009-05-07
JP2007509952A (ja)	2007-04-19
TWI359022B (en)	2012-03-01
AU2004287443B2 (en)	2011-01-27
HK1092354A1 (en)	2007-02-09

Legal Events

Date

Code

Title

Description

2008-09-15

UEP

Publication of translation of european patent specification

Ref document number: 1677761

Country of ref document: EP

Publication	Publication Date	Title
DE602004013035D1 (de)	2008-05-21	Suspension von loteprednol-etabonat und tobramycin für die topische ophthalmische anwendung
DE50312034D1 (de)	2009-11-26	Liposomale glucocorticoide
ES2170938T3 (es)	2002-08-16	Utilizacion del factor neurotrofico derivado de celulas gliales (gdnf) para el tratamiento de las deficiencias auditivas.
WO2005096990A3 (en)	2007-02-08	Novel modification of medical prostheses
AU2003303384A8 (en)	2004-07-22	Uses of mammalian cytokine; related reagents
BRPI0410503B8 (pt)	2021-05-25	composição tópica e uso da composição
RU2010123052A (ru)	2011-12-20	Авенантрамидсодержащие композиции
DE60138549D1 (de)	2009-06-10	Topische gel-abgabesysteme zur behandlung von hauterkrankungen
DE60233212D1 (de)	2009-09-17	Immunstimulierende beschichtung für chirurgische vorrichtungen
IL154888A (en)	2013-12-31	Aqueous Pharmaceutical Gel Preparation Containing At least One Vitamin D or One Vitamin D Analog At least One Corticosteroid
CA2342211A1 (en)	2000-04-06	Antibiotic compositions for treatment of the eye, ear and nose
TR200301613T2 (tr)	2004-08-23	Sapogenin türevleri, bunların sentezi ve kullanımı, bunların kullanım metotları.
DE60105448D1 (de)	2004-10-14	Feste dispersionen mit nitrataktiven wirkstoffen
BR0107691A (pt)	2005-03-22	Sapogeninas substituìdas e seu uso
EA200301022A1 (ru)	2004-02-26	Гормональная заместительная терапия
AR025923A1 (es)	2002-12-18	Nueva combinacion de loteprednol y antihistaminicos
WO2006073786A3 (en)	2006-10-12	Ophthalmic compositions comprising steroid and cyclosporine for dry eye therapy
WO2000018387A3 (en)	2000-07-06	Antibiotic compositions for treatment of the eye, ear and nose
ATE270554T1 (de)	2004-07-15	Kombination der progesteron und mifepristone für krebs-therapie
PT1492773E (pt)	2009-05-07	Compostos de 4-(heterociclilo)-benzenossulfoximinapara o tratamento da inflamação
PT1343472E (pt)	2006-10-31	Pulverizacao nasal tixotropica
SG158916A1 (en)	2010-02-26	Nitrooxy derivatives op glucocorticoids
ATE390124T1 (de)	2008-04-15	Behandlung von mastitis mit einer kombination aus prednisolon und cephalosporin
WO2004010934A3 (en)	2004-10-07	Methods for the use of neurotoxin in the treatment of urologic disorders
DK1455849T3 (da)	2006-04-03	Sårbehandlingsanordning